Background: Several studies have focused on the association between peroxisome proliferators-activated receptor gamma (PPARG) polymorphism and diabetic nephropathy (DN); however, the results of these studies were inconsistent, and until now, no population-based study has focused on the impact of PPARG gene-abdominal obesity interaction on DN risk. The aim of this study was to investigate the impact of PPARG polymorphisms and its interaction with abdominal obesity on DN risk in the Chinese Han population. Methods: A total of 848 patients with type 2 diabetes mellitus, including 420 DN patients and 428 controls were recruited. Generalized multifactor dimensionality reduction (GMDR) and logistic regression model were used to examine the association and interaction between single nucleotide polymorphism and abdominal obesity on DN; OR and 95% CI were calculated. Results: We found a significant association between CG or GG in rs1805192 and increased DN risk. DN risk was higher in the carriers of CG or GG genotype of rs1805192 than those with CC genotype; OR (95% CI) was 1.31 (1.11-1.58). GMDR analysis suggested a significant 2-locus model (p = 0.0107) involving rs1805192 and abdominal obesity, indicating a potential gene-environment interaction between rs1805192 and abdominal obesity. Overall, the 2-locus models had a cross-validation consistency of 10 of 10, and the testing accuracy of 62.17%. Conclusions: Our results support an important association between rs1805192 minor allele (G allele) of PPARG and increased DN risk; the interaction analysis showed a combined effect of interaction between rs1805192 and abdominal obesity on DN risk. The results obtained from this study are meaningful for studies on individualized PPARG agonist in treating DN for different persons, such as abdominal obese or non-abdominal obese subject.

1.
Ayodele OE, Alebiosu CO, Salako BL: Diabetic nephropathy - a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc 2004;96:1445-1454.
2.
Astrup AS, Tarnow l, Rossing P, hansen BV, hilsted J, Parving HH: Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006;29:334-339.
3.
Moczulski DK, Rogus JJ, Antonellis A, Warram JH, Krolewski AS: Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q: results of novel discordant sib-pair analysis. Diabetes 1998;47:1164-1169.
4.
Guan Y, Zhang Y, Schneider A, Davis L, Breyer RM, Breyer MD: Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Renal Physiol 2001;281:F1036-F1046.
5.
Cha DR, Zhang X, Zhang Y, Wu J, Su D, Han JY, Fang X, Yu B, Breyer MD, Guan Y: Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 2007;56:2036-2045.
6.
Bhaskar LV, Mahin S, Ginila RT, Soundararajan P: Role of the ACE ID and PPARG P12A polymorphisms in genetic susceptibility of diabetic nephropathy in a South Indian population. Nephrourol Mon 2013;5:813-817.
7.
Wang L, Teng Z, Cai S, Wang D, Zhao X, Yu K: The association between the PPARγ2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects. Diagn Pathol 2013;8:118.
8.
Preble WE: Obesity: observations on one thousand cases. Boston Med Surg J 1923;188:617-621.
9.
Meguro S, Kabeya Y, Tanaka K, Kawai T, Tomita M, Katsuki T, Oikawa Y, Atsumi Y, Shimada A, Tanaka M, Irie J, Saisho Y, Itoh H: Past obesity as well as present body weight status is a risk factor for diabetic nephropathy. Int J Endocrinol 2013;2013:590569.
10.
Chen HM, Shen WW, Ge YC, Zhang YD, Xie HL, Liu ZH: The relationship between obesity and diabetic nephropathy in China. BMC Nephrol 2013;14:69.
11.
Luo W, Guo Z, Wu M, Hao C, Hu X, Zhou Z, Zhou Z, Yao X, Zhang L, Liu J: Association of peroxisome proliferator-activated receptor α/δ/γ with obesity, and gene-gene interaction, in the Chinese Han population. J Epidemiol 2013;23:187-194.
12.
Alwakeel JS, Al-Suwaida A, Isnani AC, Al-Harbi A, Alam A: Concomitant macro and microvascular complications in diabetic nephropathy. Saudi J Kidney Dis Transpl 2009;20:402-409.
13.
Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. World Health Organ Tech Rep Ser 2000;894:i-xii, 1-253.
14.
Lou XY, Chen GB, Yan L, Ma JZ, Zhu J, Elston RC, Li MD: A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet 2007;80:1125-1137.
15.
Zhang H, Zhu S, Chen J, Tang Y, Hu H, Mohan V, Venkatesan R, Wang J, Chen H: Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care 2012;35:1388-1393.
16.
Liu G, Zhou TB, Jiang Z, Zheng D, Yuan F, Li Y, Hu H, Chen Z: Relationship between PPARγ Pro12Ala gene polymorphism and type 2 diabetic nephropathy risk in Asian population: results from a meta-analysis. J Recept Signal Transduct Res 2014;34:131-136.
17.
Pi-Sunyer FX: Weight loss in type 2 diabetic patients. Diabetes Care 2005;28:1526-1527.
18.
Ramachandran A, Ma RC, Snehalatha C: Diabetes in Asia. Lancet 2010;375:408-418.
19.
Wu Y: Overweight and obesity in China. BMJ 2006;333:362-363.
20.
Maric C, Hall JE: Obesity, metabolic syndrome and diabetic nephropathy. Contrib Nephrol 2011;170:28-35.
21.
Shen WW, Chen HM, Chen H, Xu F, Li LS, Liu ZH: Obesity-related glomerulopathy: body mass index and proteinuria. Clin J Am Soc Nephrol 2010;5:1401-1409.
22.
Saiki A, Nagayama D, Ohhira M, Endoh K, Ohtsuka M, Koide N, Oyama T, Miyashita Y, Shirai K: Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes (Lond) 2005;29:1115-1120.
23.
Andreotti F, Rio T, Lavorgna A: Body fat and cardiovascular risk: understanding the obesity paradox. Eur Heart J 2009;30:752-754.
24.
Masugi J, Tamori Y, Mori H, Koike T, Kasuga M: Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000;268:178-182.
25.
Luo W, Cao J, Li J, He W: Adipose tissue-specific PPARgamma deficiency increases resistance to oxidative stress. Exp Gerontol 2008;43:154-163.
26.
Svensson M, Eriksson JW: Insulin resistance in diabetic nephropathy - cause or consequence? Diabetes Metab Res Rev 2006;22:401-410.
27.
Chen HM, Shen WW, Ge YC, Zhang YD, Xie HL, Liu ZH: The relationship between obesity and diabetic nephropathy in China. BMC Nephrol 2013;14:69.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.